Drug Profile
C 4699
Alternative Names: C-4699Latest Information Update: 18 Feb 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 28 Jan 2005 Phase-I clinical trials in Urinary incontinence in USA (unspecified route)